News & Events | Alkermes
Nov 7, 2024 · Sharing stories of patients, employees and communities. View the latest Alkermes news, events and press releases.
Alkermes – A Global Biopharmaceutical Company
Nov 7, 2024 · Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices. View our latest report.
Alkermes Announces FDA Approval of LYBALVI™ for the …
Jun 1, 2021 · Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder. PDF Version. -- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain ---- Commercial Launch Planned for Fourth Quarter 2021 ---- Company to Host Investor Conference Call Today at 8:30 a.m. ET ...
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ...
DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating ...
Alkermes Announces Positive Topline Results From Phase 1b …
DUBLIN, April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily ...
Alkermes Announces Clinical Trial Collaboration and Supply …
DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), Alkermes ...
Leadership, Management Team & Board of Directors | Alkermes
Under the leadership of Richard Pops, CEO, and other seasoned executives, Alkermes has grown to become a publicly traded, global biopharmaceutical company.
Alkermes plc Reports Third Quarter 2022 Financial Results
Nov 2, 2022 · Alkermes plc Reports Third Quarter 2022 Financial Results. PDF Version. — Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio —. — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —. — Company Announces Intent to Separate Oncology Business —.
Leading a New Era of Patient-Inspired Neuroscience - Alkermes
Alkermes enters 2024 as a standalone, focused neuroscience company poised for continued growth, following a transformational year for our business. With an established commercial portfolio providing real-world insight into conditions facing patients with serious mental illness, and a research pipeline built around our core medicinal chemistry ...
Alkermes plc Reports First Quarter 2023 Financial Results
Apr 26, 2023 · Alkermes reiterates its financial expectations for 2023, as set forth in its press release dated Feb. 16, 2023. Separation of Oncology Business. Alkermes continues to make meaningful progress on the previously announced planned …